Drug intelligence / Profile preview

RHYB-825

Development stage: Preclinical
Lead developer: Rhythm Pharmaceuticals
Modality: Small Molecules

Overview

RHYB-825, formerly known as XNV-825, is a preclinical small-molecule inhibitor being developed by Rhythm Pharmaceuticals for the treatment of congenital hyperinsulinism (CHI), a rare endocrine disorder. Rhythm Pharmaceuticals acquired the full global rights to RHYB-825 through its acquisition of Xinvento B.V., leveraging its expertise in rare pediatric endocrinology and genetic diseases.

Other names: XNV-825XNV825XNV 825

Beyond the preview

Go deeper on RHYB-825.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHYB-825.

Explore the full profile